Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 15, 2020 - Issue
Submit an article Journal homepage
126
Views
2
CrossRef citations to date
0
Altmetric
Study Protocol

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol

Roland Buhl1 Pulmonary Department, Johannes Gutenberg University Mainz, Mainz, GermanyCorrespondence[email protected]
,
Michael Dreher2 Clinic of Cardiology, Pneumology, Angiology and Internal Medicine Intensive Care, University Hospital RWTH Aachen, Aachen, Germany
,
Stephanie Korn1 Pulmonary Department, Johannes Gutenberg University Mainz, Mainz, Germany
,
Christian Taube3 Clinic for Pneumonology, University Medicine Essen – Ruhrlandklinik, Essen, Germany
,
Christian Stock4 Biostatistics + Data Sciences Corp, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyORCID Iconhttps://orcid.org/0000-0002-3493-3234
ORCID Icon,
Christoph M Zehendner5 HP Country Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
,
Anke Kondla5 HP Country Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyORCID Iconhttps://orcid.org/0000-0002-1412-8510
ORCID Icon &
Claus F Vogelmeier6 Department of Pneumology, University Hospital of Giessen and Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany
 show all
Pages 2601-2608 | Published online: 22 Oct 2020

References

  • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). Published 2019 Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed 214, 2020.
  • KardosP, VogelmeierC, BuhlR, CrieeCP, WorthH. The prospective non-interventional DACCORD study in the national COPD registry in Germany: design and methods. BMC Pulm Med. 2015;15:2. doi:10.1186/1471-2466-15-225578330
  • BuhlR, MaltaisF, AbrahamsR, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969–979. doi:10.1183/09031936.0013601425573406
  • WedzichaJA, BanerjiD, ChapmanKR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa151638527181606
  • BeehKM, DeromE, Echave-SustaetaJ, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study). Int J Chron Obstruct Pulmon Dis. 2016;11:193–205. doi:10.2147/COPD.S9505526893551
  • LipsonDA, BarnhartF, BrealeyN, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
  • BuhlR, CrieeCP, KardosP, et al. Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study. Int J Chron Obstruct Pulmon Dis. 2018;13:2557–2568. doi:10.2147/COPD.S16995830197512
  • VoorhamJ, CorradiM, PapiA, et al. Comparative effectiveness of triple therapy versus dual bronchodilation in COPD. ERJ Open Res. 2019;5(3):00106–02019. doi:10.1183/23120541.00106-201931497610
  • RabeKF. Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies. Proc Am Thorac Soc. 2006;3(3):270–275. doi:10.1513/pats.200601-002SF16636097
  • BeehKM. A descriptive analysis of COPD patients in a large cohort in private practices in Germany. Am J Respir Crit Care Med. 2004;169:A603.
  • HalpinDMG. The role of tiotropium+olodaterol dual bronchodilator therapy in the management of chronic obstructive pulmonary disease. Tuberc Respir Dis. 2018;81(1):13–18. doi:10.4046/trd.2017.0098
  • IngelheimB. Spiolto® Respimat® (tiotropium/olodaterol) is Boehringer Ingelheim’s new advance in COPD maintenance therapy. Published 2018 Available from: https://www.boehringer-ingelheim.com/copd/copd/information-tovito-clinical-trial-program. Accessed 1018, 2019.
  • GrafJ, JörresRA, LuckeT, NowakD, VogelmeierCF, FickerJH. Medical treatment of COPD: an analysis of guideline-adherent prescribing in a large national cohort (COSYCONET). Dtsch Arztebl Int. 2018;155(37):599–605. doi:10.3238/arztebl.2018.059930282573
  • KardosP, VogelmeierC, WorthH, et al. A two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: the DACCORD observational study. Respir Med. 2017;124:57–64. doi:10.1016/j.rmed.2017.02.00728284322
  • TsiligianniIG, AlmaHJ, de JongC, et al. Investigating sensitivity, specificity, and area under the curve of the clinical COPD questionnaire, COPD Assessment Test, and modified Medical Research Council scale according to GOLD using St George’s Respiratory Questionnaire cutoff 25 (and 20) as reference. Int J Chron Obstruct Pulmon Dis. 2016;11:1045–1052. doi:10.2147/COPD.S9979327274226
  • VogelmeierC, BuhlR, BurghuberO, et al. Guideline for the diagnosis and treatment of COPD patients-issued by the German Respiratory Society and the German Atemwegsliga in cooperation with the Austrian Society of Pneumology. Pneumologie. 2018;72(4):253–308. doi:10.1055/s-0043-12503129523017
  • BestallJC, PaulEA, GarrodR, GarnhamR, JonesPW, WedzichaJA. Usefulness of the medical research council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586. doi:10.1136/thx.54.7.58110377201
  • DoddJW, HoggL, NolanJ, et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax. 2011;66(5):425–429. doi:10.1136/thx.2010.15637221398686
  • HerlandK, AkselsenJ-P, SkjønsbergOH, BjermerL. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med. 2005;99(1):11–19. doi:10.1016/j.rmed.2004.03.02615672843
  • DhandR, EicherJ, HanselM, JostI, MeisenheimerM, WachtelH. Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler. Int J Chron Obstruct Pulmon Dis. 2019;14:509–523. doi:10.2147/COPD.S19063930880941

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.